International AIDS Society

Track C - Prevention Science

Prevention of Mother-to-Child Transmission

C1 Reducing pre-partum and intra-partum transmission to infants 
C2 Reducing post-partum transmission in infants
C3 Strategies to increase HIV testing in pregnant women and their partners
C4 Increasing coverage and quality of PMTCT programmes
C5 PMTCT services for sex workers and other marginalized groups

Reproductive Choices and Maternal Health

C6 Integration of family planning and HIV services
C7 Reproductive choices and interventions for HIV infected women and uninfected women including discordant couples 
C8 Opportunities for reducing maternal deaths

Novel Means of Biomedical Prevention

C9 Preclinical prophylactic drug and vaccine development
C10 Preclinical vaccine development
C11 Animal models evaluation
C12 Early stage clinical trials of new molecules
C13 Establishing cohorts to study HIV incidence, preventive interventions, natural history

Measuring and Supporting Adherence in Prevention Trials

C14 Barriers and facilitators to adherence to biomedical HIV prevention strategies
C15 Biomedical measurements of adherence, including electronic devices and bioassays
C16 Behavioural strategies to support adherence

ARVs for Prevention

C17 Pre-exposure prophylaxis (systemic)
C18 Post-exposure prophylaxis (systemic)
C19 Pre- and post-exposure prophylaxis (topical) / microbicides
C20 Treatment as prevention
C21 Pharmacology of ARVs for HIV prevention (PK, PD)
C22 Monitoring resistance in topical and oral PrEP studies 

Reducing HIV Transmission

C23 Blood, organ, tissue and medical injection safety
C24 Male circumcision
C25 STI control to prevent HIV transmission
C26 Novel approaches for HIV testing
C27 HIV testing in couples

Optimising Multi-Component Interventions 

C28 Optimising multicomponent interventions for different epidemic settings and populations at risk
C29 Design of combination prevention interventions
C30 Modelling impact of combination prevention interventions
C31 Increasing access and coverage of interventions
C32 Evaluating the impact of combination prevention
C33 Cost-effectiveness and  interventions

Feasibility and Impact of Structural Interventions

C34 Economic-based HIV interventions (i.e., micro-capital/cash transfer/contingency management/housing/poverty reduction programmes)
C35 Assessing impact/cost-effectiveness of structural interventions
C36 Gender sensitization, empowerment and violence reduction
C37 Collectivization, mobilization, stigma reduction programmes
C38 Policy-level HIV interventions including legal-policy reform and taxation

Epidemiology, Methodology and Surveillance

C39 Measuring impact of prevention interventions at a population level
C40 Novel strategies for measuring incidence rates
C41 New and novel clinical trial designs for HIV prevention e.g. adaptive designs
C42 Novels assays and strategies for measuring incidence rates in cross-sectional samples
C43 Second and third generation surveillance strategies
C44 Assessment of population viral load in epidemiology studies 
C45 Modelling the epidemiological impact of large scale prevention programs: approaches and results
C46 Innovations in the measurement of sensitive behaviours and adherence

Prevention Strategies for Special Populations

C47 Reducing risk in adolescents
C48 Strategies for identifying most at risk populations (MARPs)
C49 Discordant couples studies
C50 Prevention in prison settings
C51 Prevention among MSM
C52 Prevention among sex workers
C53 Prevention among IDU and non-IDU substance using populations, including alcohol abusers
C54 Prevention among populations with multiple co-occurring epidemics/syndemics
C55 Prevention among emerging vulnerable populations
C56 Prevention strategies for cross-nationally connected populations of MSM, sex workers and clients and IDUs
C57 Use of internet, social media and other e-devices to provide and link to prevention and treatment services
C58 Identification of acute and recent HIV infection
C59 Prevention interventions during acute infection
C60 Prevention in positives

Social and Cultural Determinants of HIV Risk

C61 Community-based HIV prevention research designs
C62 Network studies of risk behaviours and their implications for prevention


C63 Integrating social science research into clinical and biomedical intervention trial
C64 Ethical issues in biomedical prevention, including standard of care
C65 Community involvement in biomedical prevention

Back to categories